OAM
RGLS

Oxford Asset Management’s Regulus Therapeutics RGLS Stock Holding History

Oxford Asset Management’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-4,018
Closed -$1.39M – 842
2016
Q2 		$1.39M Sell
4,018
-518
-11% -$371K 0.05% 426
2016
Q1 		$3.77M Buy
4,536
+2,363
+109% +$1.88M 0.11% 237
2015
Q4 		$2.33M Buy
+2,173
New +$2.18M 0.06% 366

Other funds holding RGLS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
SDIC
South Dakota Investment Council Sioux Falls, South Dakota $5.84B AUM 30.42% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Oxford Asset Management's RGLS Position: Q3 2016 in Review

Oxford Asset Management sold out of Regulus Therapeutics (RGLS) in Q3 2016, closing a stake of 4,018 shares — an estimated $1.39M sold.

Oxford Asset Management first reported a position in RGLS in Q4 2015 and held it in 3 quarters. The position peaked at $3.77M in Q1 2016. 83 funds tracked by Wall St. Rank hold RGLS as of Q3 2016.

  • Oxford Asset Management reported no remaining Regulus Therapeutics position as of Q3 2016 after selling out during the quarter.
  • Oxford Asset Management sold 4,018 Regulus Therapeutics shares in Q3 2016, an estimated $1.39M.
  • Oxford Asset Management first reported a position in Regulus Therapeutics in Q4 2015 and held it in 3 quarters.
  • Oxford Asset Management's Regulus Therapeutics position peaked at $3.77M in Q1 2016.
  • 83 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q3 2016.

Based on Oxford Asset Management's 13F filing for Q3 2016, filed 14 Nov 2016.